PCRX — Pacira Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $1.22bn
- $1.46bn
- $674.98m
- 97
- 68
- 38
- 76
Annual cashflow statement for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11 | 146 | 42 | 15.9 | 42 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 71.1 | 72 | 69.8 | 62.2 | 67.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.14 | -33.8 | -25.5 | -16.4 | -45.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 70.5 | 77 | 126 | 145 | 155 |
| Capital Expenditures | -10.2 | -37.8 | -45.9 | -30.1 | -15.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -118 | -240 | 25.1 | -195 | 92.7 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -128 | -278 | -20.8 | -225 | 77.5 |
| Financing Cash Flow Items | -6.86 | -38.7 | -5.17 | 0 | -5.86 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.67 | 222 | 381 | -402 | -183 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -54.3 | 21.7 | 486 | -481 | 49.2 |